Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?

NCT04477876 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT04477876
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04477876 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2020
Completion date
December 15, 2027
Enrollment
55 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma